Katrin Sproesser

Join this workshop to explore how emerging innate immune cell engagers are reshaping the next generation of T-cell engager therapeutics and overcoming resistance, improving safety, and expanding potential in solid tumors.

• Identifying high-value innate immune targets, including NK activating and inhibitory receptors, and macrophage checkpoint pathways to overcome tumor immune suppression
• Evaluating the advantages and limitations of NK, macrophage, and multi-lineage engagers compared to traditional T-cell engagers
• Exploring engineering considerations for multi-functional molecules, including avidity, geometry, immune synapse formation, and balancing potency with safety
• Discussing appropriate preclinical and translational models to evaluate innate immune engagement, including humanized systems and tumor microenvironment platforms
• Defining safety considerations and the minimum preclinical data package required to justify advancing NK, macrophage, or multi-lineage engagers into clinical development